期刊文献+

低剂量沙利度胺治疗多发性骨髓瘤27例的疗效分析 被引量:7

下载PDF
导出
摘要 目的结合临床实践经验,开展低剂量沙利度胺联合化疗治疗多发性骨髓瘤(MM)的疗效分析。方法采用回顾性分析法,以桂林医学院附属医院收治的MM患者为研究对象,将其临床治疗等资料进行总结,分析治疗前后患者M蛋白量、骨髓浆细胞比例以及血红蛋白浓度变化情况,观察患者的不良反应,探讨应用低剂量沙利度胺联合化疗的治疗疗效。结果对初发和复发难治病例的总有效率为62.96%,平均血红蛋白浓度、骨髓浆细胞比例以及血M蛋白量三项指标治疗前后比较,差别有统计学意义(P<0.05)。应用小剂量沙利度胺治疗中出现如下不良反应:便秘腹胀21例,乏力20例,周围神经病变10例,皮疹瘙痒5例,颜面水肿4例。反应均较轻微,经对症处理后均患者的不良反应症状均缓解,可坚持服药。结论低剂量沙利度胺联合化疗能取得较好的疗效,不良反应轻,此种方法治疗MM是安全有效的,值得临床推广应用。
出处 《中国医药指南》 2011年第5期97-98,共2页 Guide of China Medicine
  • 相关文献

参考文献5

二级参考文献29

  • 1岑海燕,陈钰.反应停联合VAD方案治疗多发性骨髓瘤的疗效[J].中国肿瘤生物治疗杂志,2006,13(5):384-386. 被引量:3
  • 2Blade J, Samson D, Recce D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantion. Myeloma Subcommittee of the EBMT. European Group For Blood and Marrow Transplant[J]. Br J Haematol, 1998, 102(5): 1115-1123.
  • 3Fermand JP, Katsahian S ,Divine M, et al. High dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55-65 years: long-term results of randomized control trial from the Group Myeloma-Autograffe[J]. J Clin Lncol, 2005, 23(36): 9227-9233.
  • 4Hus M, Dmoszynska A, Manko, J, et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma[J]. Br J Cancer, 2004, 91 (11): 1873-1879.
  • 5Antonio P, Sara B, Tommas C, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisune alone in elderly patients with multiple myeloma: randomized controlled trial[J]. Lancet, 2006, 367(9513): 825-831.
  • 6Shajio K, Vincent RS. Thalidomide and lenalidomide in the treatment of multiple myeloma[J]. Eur J Cancer, 2006, 42(11): 1612-1622.
  • 7Michel A, Jean-luc H, Serge L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma [J]. Blood, 2006, 108(15): 3289-3294.
  • 8singlal S, mehca J, Desikan R, et al. Antihamor activity of thalidomidein refractory multiple myeloma [ J ]. N Engl J Med, 1999,341 : 1565 - 1572.
  • 9Weber D, Rankink, Gavino M, et al. Thalidomide alone or with dexame, thasone for prewiously untreated[J]. Multiple Myeloma J Clin Oncol,2003,21(1) : 16.
  • 10Palumbo A, Ciaccone L, Bertola A,et al,low-dose thalido- mide plus dexamethas one is an effective salvage therapy for advanced myeloma[ J]. Hematologica, 2001,86(4) : 399.

共引文献12

同被引文献38

  • 1高津,傅晋翔,张宏.T-VAD和VAD方案治疗多发性骨髓瘤的疗效观察[J].中国血液流变学杂志,2008,18(1):75-77. 被引量:6
  • 2唐雪娟,任莉.低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的临床分析[J].中国生化药物杂志,2014,34(4):113-115. 被引量:21
  • 3徐茂忠,徐昕,赵钰.低剂量沙利度胺联合化疗治疗难治性多发性骨髓瘤7例[J].中国交通医学杂志,2006,20(2):147-148. 被引量:2
  • 4赫玉书.白细胞疾病基础理论与临床.上海:上海科学技术出版社,2006:711.
  • 5Dmoszynska A. Diagnosis and the current trends inmuhiple myeloma therapy[J]. Pol Arch Med Wewn,2008,118 (10) :563- 566.
  • 6Gallamini A, Stelitano C, Calvi R, et al. Peripheral T - cell lymphoma unspecified( PTCL- U) :a new prognostic model from a retrospective muhicentric chnical study [ J ]. Blood, 2004, 103 (7) :2474-2479.
  • 7Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAPAMPVECP compared with biweekly CHOP for adult T - cell leukemia -lymphoma: Japan Clinical Oncology Group Study JCOG9801 [J]. J ClinOncol, 2007, 25(34) :5458-5464.
  • 8Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity [J]. J Support 0ncol,2003 ,I (3) :194-205.
  • 9惠双.低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的l临床观察[J],2011,6(2):162-163.
  • 10Barlogie B, Kyle RA, Anderson KC, et al. Standard chemothera- py compared with high-dose chemoradiotherapy for multiple myelo- ma: final results of phase Ⅲ US Intergroup Trial S9321. J Clin Oncol,2006,24 (6) :929-936.

引证文献7

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部